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An alternative approach to reduce vascular complicationsGuido Gelpi, MD, Claudia Romagnoni, MD, Paolo Danna, MD, and Carlo Antona, MD, Milano, ItalyTABLE 1. Before and after procedural data
Data Value
Baseline characteristics
Age, y 84  5
NYHA III-IV 2 (28.57)
Diabetes mellitus 4 (57.14)
Coronary artery disease 2 (28.57)
COPD 3 (42.86)
Renal dysfunction 2 (28.57)
Logistic EuroSCORE,% 22  9
Left ventricle ejection fraction,% 44  8
Previous cardiac intervention 4 (57.14)
Previous endovascular procedure 2 (28.57)
Porcelain aorta 2 (28.57)Transcatheter aortic valve implantation (TAVI) is a well-
recognized therapeutic option for high-risk patients with
aortic stenosis. Its application is booming, and new devices
will soon increase the chance to treat more patients. Despite
encouragingly good results, vascular complications remain
the Achilles’ heel of this procedure. According to Valve
Academic Research Consortium (VARC) criteria, major
vascular complications vary between 10.7% and 15.3%
in predicting 30-day mortality.1,2 The rate of vascular
complications has been diminishing thanks to the
downsizing of the introducer from 24F to 18F and
the choice of alternative vascular access besides the
transfemoral (subclavian, transaortic, and transapical).Procedural outcome
Successful valvuloplasty 7 (100)





Postprocedural gradient, mmHg 9  3
Safety end points at 30 d follow-up according to VARC definition
Overall death 0 (0)
Stroke 0 (0)
Major bleeding 0 (0)CLINICAL EXPERIENCE
Among 51 patients treated with TAVI between July 2009
and August 2012, 7, with vascular access less than 6 mm,
were deemed not suitable for the transapical or transaortic
approach. The Heart Team opted to implant the Medtronic
CoreValve (Medtronic, Minneapolis, Minn) through
the femoral or subclavian artery without the introducer
(sheathless). Device success was 100%, and no vascular
complication occurred. According to VARC criteria, before
and after procedural data are reported in Table 1.Major vascular complications 0 (0)
Minor vascular complications 0 (0)
PM implantation 1 (14.29)
Values are given as mean  SD or number (percentage). NYHA, New York Heart
Association; COPD, chronic obstructive pulmonary disease; VARC, Valve Academic
Research Consortium; PM, pacemaker; EuroSCORE, European System for Cardiac
Operative Risk Evaluation.SURGICAL TECHNIQUE
With local anesthesia and minimal sedation, we
perform a surgical incision of 4 cm for femoral and
6 cm for subclavian access; the artery is secured
with two tourniquets proximally and distally, and two
5-0 prolene-pledgeted purse strings are placed around
the incision site for hemostasis. A 6F sheath is inserted
for guide positioning, then replaced with a 12F for bal-
loon valvuloplasty; finally, after removing the 12F sheath,
the CoreValve System is gently inserted directly into the
artery on a stiff wire. A further small extension of theFrom the Cardiovascular Surgery Department, ‘‘Luigi Sacco’’ University General
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240 The Journal of Thoracic and Cardiovascular Surgartery incision avoids any vessel damage. If postdilatation
is required, the system is retrieved and the 12F is reposi-
tioned, securing hemostasis with the purse string. The
artery is closed directly at the end of the procedure.DISCUSSION
As cardiovascular surgeons, we are used to the ‘‘sheath-
less technique’’ because of practice with sheathless
endovascular prosthesis (ie, Endurant; Medtronic). Accu-
track (Medtronic) is the CoreValve delivery system that
allows navigating and delivering the valve in the correct
position. All 4 different sizes of the CoreValve are mounted
into the 18F Accutrack that protects and keeps the valve
crimped, with a smooth plastic cover. The maximum outer
diameter of the Accutrack is 18F (6 mm) for the first 7 cm,ery c July 2013
FIGURE 1. Sheathless femoral transcatheter aortic valve implantation (TAVI) in a patient with aortoiliac endoprosthesis (A) and in a patient with severe
calcifications of aortic carrefour (B and C); sheathless right subclavian TAVI in a patient with previous coronary artery bypass grafting, porcelain aorta,
diseased femoral and iliac access, occluded left subclavian artery, and small right subclavian artery (D-F). Arrows indicate the axial computed tomography
scan details. The computed tomography scan vessel diameters are in green.
Surgical Techniques12F for the middle 14.6 cm, and 15F for the last 90.7 cm,
whereas the outer diameter of a compatible 18F introducer
is 7.2 mm. The difference between a sheath and sheathless
procedure is only 1.2 mm, but it means a reduction in
access vessel diameter of 16.7%. This technique allows
us to avoid keeping a stiff 30-cm length introducer in the
access vessel for the entire procedure. The 6-mm delivery
system passes through the vascular access for a few seconds
and, for just 7 cm, reducing the risk of artery recoil or
dissection. The smoother Accutrack’s nose follows
curvature or indentation of the artery better than the rigid
introducer’s dilatators. Moreover, avoiding introducer
obstruction, subclavian sheathless access allows a greater
flow to the internal thoracic artery (ITA) also in case of
patent ITA to the left anterior descending artery.3 Indeed,
thanks to the flexibility of the delivery system, it becomes
possible to perform a TAVI procedure even in case of
important vessel tortuosity or in case of previous aortic
stent or endovascular prosthesis implantation (Figure 1).
As reported by Hayashida et al,4 a sheath to femoral artery
ratio (SFAR) of 1.05 predicted a statistically significantly
higher rate of VARC major complications and 30-dayThe Journal of Thoracic and Camortality. The authors identified, for an 18F introducer,
a minimal noncalcified ileofemoral artery access of
6.5 mm and of 7.2 mm for calcified artery access. A
sheathless procedure allows 6-mm artery access.
The main drawback of this off-label approach is the
impossibility to recapture the CoreValve. However, also
using the introducer, this procedure may be difficult and
risky (particularly for the subclavian access).5 To minimize
the risk of suboptimal positioning or device displacement
during a sheathless procedure, we always deploy the
CoreValve under rapid pacing. With the advent of new
device generation, with a smaller diameter, a sheathless
technique will remain a valid option, particularly in cases
of small and diseased vessels.
CONCLUSIONS
Patients with major vascular complications had a 2-fold
increase in mortality, and vascular complications are strictly
related to SFAR.4 The sheathless technique, allowing
a smaller 16.7% artery diameter, is an alternative to
standard access. The ‘‘Heart Team’’ should consider this
off-label option when conventional access is precludedrdiovascular Surgery c Volume 146, Number 1 241
Surgical Techniquesand to avoid intricately more invasive access, such as
transaortic and transapical, that requires general anesthesia.
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